All In Biotech

Drug Trial Radar · NCT06555263

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects With Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1

Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Aug 21, 2024

Primary completion

May 1, 2025

Study completion May 1, 2025

Sponsor

Lead sponsor
Sutro Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1

Conditions

  • Lung Cancer
  • Lung Cancer Metastatic
  • Lung Cancer, Nonsmall Cell
  • Lung Cancer Non-Small Cell Stage IIIB
  • Lung Cancer Non-small Cell Stage IV
  • Lung Cancer, Non-small Cell

Interventions

  • Luveltamab tazevibulinDrug

    Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload, yielding a homogenous ADC with a drug antibody ratio of four. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: up to 24 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • UC San Diego Health - Moores Cancer Center

    La Jolla, California

  • Georgetown University Medical Center - Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia

  • Florida Cancer Specialists & Research Institute (FCS)

    Lake Mary, Florida

  • Tampa General Hospital - Cancer Center of South Florida

    Tampa, Florida

  • HealthPartners Frauenshuh Cancer Center

    Saint Louis Park, Minnesota

  • HealthPartners Cancer Center at Regions Hospital

    Saint Paul, Minnesota

  • Mary Crowley Cancer Research

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.